Daniel Anderson, PhD

Daniel G. Anderson, PhD, is a biomaterials researcher and a pioneer of cell encapsulation for type 1 diabetes. At MIT in Cambridge he is a professor in the Department of Chemical Engineering and the Koch Institute for Integrative Cancer Research. He also holds appointments in the Institute for Medical Engineering and Science and the Harvard-MIT Division of Health Sciences and Technology. For over a decade his lab has worked to protect transplanted cells from immune rejection without lifelong immunosuppression, a central problem in islet replacement. He co-founded Sigilon Therapeutics, later acquired by Lilly, to commercialize the immune-protective encapsulation technology developed in his lab. His work across medical devices, cell therapy, drug delivery, and gene therapy has produced more than 400 papers, patents, and applications.

Affiliation

Professor of Chemical Engineering, MIT

Location

Cambridge, Massachusetts, U.S.